Regeneron COVID-19 treatment enters final stage trials | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Friday
June 13, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
FRIDAY, JUNE 13, 2025
Regeneron COVID-19 treatment enters final stage trials

Coronavirus chronicle

BSS/AFP
07 July, 2020, 12:45 pm
Last modified: 07 July, 2020, 12:48 pm

Related News

  • 10 more Covid-19 cases reported in country
  • Yes, everyone really is sick a lot more often after covid
  • Pentagon's secret anti-vax campaign against China during the pandemic
  • Bangladesh reports one Covid-19 death, 37 positive cases
  • 3rd, 4th doses of Covid-19 vaccination underway

Regeneron COVID-19 treatment enters final stage trials

This trial, run jointly with the US National Institute of Allergy and Infectious Diseases (NIAID), is expected to enroll 2,000 patients in the US

BSS/AFP
07 July, 2020, 12:45 pm
Last modified: 07 July, 2020, 12:48 pm
Regeneron COVID-19 treatment enters final stage trials

The pharmaceutical firm Regeneron on Monday announced it was entering the late stages of its human clinical trials investigating a drug to both treat and prevent COVID-19.

The drug, called REGN-COV2, is a combination of two antibodies that block the coronavirus' "spike protein" which it uses to invade human cells.

The company is moving to the final Phase 3 stage of a trial to determine if its drug can prevent infection among people recently exposed to the virus — for example through a person in their household.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

This trial, run jointly with the US National Institute of Allergy and Infectious Diseases (NIAID), is expected to enroll 2,000 patients in the US.

"We are pleased to collaborate with NIAID to study REGN-COV2 in our quest to further prevent the spread of the virus with an antiviral antibody cocktail that could be available much sooner than a vaccine," said Regeneron President George Yancopoulos.

At the same time, Regeneron announced it was moving to the final stages of a trial to determine the drug cocktail's ability to treat both hospitalized and non-hospitalized COVID-19 patients.

This will involve around 1,850 hospitalized and 1,050 non-hospitalized patients in the US, Brazil, Mexico and Chile, with preliminary data expected later this summer.

Regeneron scientists evaluated thousands of antibodies harvested from genetically modified mice and from humans, identifying the two they found to be most potent against the SARS-CoV-2 virus, while not competing against each other.

The company uses a multi-antibody strategy to decrease the chances that the virus will mutate in order to evade the blocking action of a single antibody, an approach it detailed in a recent study in Science.

Last year, a triple antibody cocktail developed by Regeneron was shown to be effective against the Ebola virus.

Top News

Regeneron / Coronavirus

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • BNP Acting Chairperson Tarique Rahman and Chief Adviser  Muhammad Yunus meet at Dorchester Hotel in London, UK on 13 June 2025. Photo: CA Press Wing
    'Historic' meeting between Yunus and Tarique underway at Dorchester hotel in London
  • National Security Adviser Khalilur Rahman met with Amir Khasru Mahmud Chowdhury, a standing committee member of the BNP, at London’s Dorchester Hotel on 13 June 2025. Photo: CA Press Wing
    National Security Adviser Khalilur, BNP's Khasru hold meeting alongside Yunus-Tarique talks in London
  • Rescuers work at the scene of a damaged building in the aftermath of Israeli strikes, in Tehran, Iran, June 13, 2025. Majid Asgaripour/WANA (West Asia News Agency) via REUTERS
    Tehran retaliates with 100 drones after Israel strikes Iran's nuclear facilities, kills military leaders

MOST VIEWED

  • Wreckage of a Boeing 787 Dreamliner showing part of its registration "VT-ANB" in Ahmedabad, India, June 12, 2025. REUTERS/Amit Dave
    Air India Dreamliner crashes into Ahmedabad college hostel, kills over 290
  • File Photo of Chief Adviser Muhammad Yunus: UNB
    Prof Yunus to receive Harmony Award from King Charles today
  • Bangladesh Bank Governor Ahsan H Mansur. TBS Sketch
    Bangladesh mulls settlements with tycoons over offshore wealth: BB governor tells FT
  • Railway seeks Tk2,000cr foreign loans to revive coach assembly, modernise workshops
    Railway seeks Tk2,000cr foreign loans to revive coach assembly, modernise workshops
  • UK Prime Minister Keir Starmer, Chief Adviser Muhammad Yunus
    Disclosure of unconfirmed Yunus-Starmer meeting shows ‘diplomatic imprudence’: Analysts
  • Brother sues Latifur's daughter, widow over alleged forgery to seize control of Transcom
    Brother sues Latifur's daughter, widow over alleged forgery to seize control of Transcom

Related News

  • 10 more Covid-19 cases reported in country
  • Yes, everyone really is sick a lot more often after covid
  • Pentagon's secret anti-vax campaign against China during the pandemic
  • Bangladesh reports one Covid-19 death, 37 positive cases
  • 3rd, 4th doses of Covid-19 vaccination underway

Features

Among pet birds in the country, lovebirds are the most common, and they are also the most numerous in the haat. Photo: Junayet Rashel

Where feathers meet fortune: How a small pigeon stall became Dhaka’s premiere bird market

1d | Panorama
Illustration: Duniya Jahan/ TBS

Forget Katy Perry, here’s Bangladesh’s Ruthba Yasmin shooting for the moon

2d | Features
File photo of Eid holidaymakers returning to the capital from their country homes/Rajib Dhar

Dhaka: The city we never want to return to, but always do

4d | Features
Photo collage shows political posters in Bagerhat. Photos: Jannatul Naym Pieal

From Sheikh Dynasty to sibling rivalry: Bagerhat signals a turning tide in local politics

6d | Bangladesh

More Videos from TBS

'Historic' meeting between Yunus and Tarique underway in London

'Historic' meeting between Yunus and Tarique underway in London

23m | TBS Today
Iran warns Israel of severe retaliation

Iran warns Israel of severe retaliation

1h | TBS World
Global oil prices soar

Global oil prices soar

2h | TBS World
What did Iran say in response to the Israeli attack?

What did Iran say in response to the Israeli attack?

2h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net